Enovis Corp Cash Flow Conversion Efficiency

Latest as of June 2026: 0.051x

Enovis Corp cash flow conversion efficiency. Based on the latest financial reports, Enovis Corp (ENOV) has a cash flow conversion efficiency ratio of 0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($75.03 Million) by net assets ($1.48 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Enovis Corp (2005–2025)

Cash flow conversion efficiency of Enovis Corp from 2005 to 2025. This chart illustrates how Enovis Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ENOV stock price for real-time trading data and today's change.

Enovis Corp Cash Flow Conversion Ratio Explained

Enovis Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Enovis Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Enovis Corp ranked by their cash flow conversion efficiency. Also see how much is Enovis Corp worth for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Lemon Tree Hotels Limited
NSE:LEMONTREE
0.113x
Fermi Inc.
NASDAQ:FRMI
-0.047x
Glenveagh Properties PLC
IR:GVR
0.096x
China Reform Health Management and Services Group Co Ltd
SHE:000503
-0.066x
Ningbo Fujia Industrial Co Ltd
SHG:603219
0.020x
Ventyx Biosciences Inc
NASDAQ:VTYX
-0.091x
International General Insurance Holdings Ltd
NASDAQ:IGIC
0.162x
Wuxi Dk Electronic Materials Co Ltd
SHE:300842
0.282x

Annual Cash Flow Conversion Efficiency for Enovis Corp (2005–2025)

The table below shows the annual cash flow conversion efficiency of Enovis Corp from 2005 to 2025. Review ENOV cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $1.49 Billion $217.29 Million 0.146x +229.05%
2024-12-31 $2.56 Billion $113.50 Million 0.044x +12.17%
2023-12-31 $3.42 Billion $134.99 Million 0.039x +343.71%
2022-12-31 $3.45 Billion $-55.86 Million -0.016x -121.20%
2021-12-31 $4.66 Billion $356.10 Million 0.076x -9.22%
2020-12-31 $3.59 Billion $301.94 Million 0.084x +124.26%
2019-12-31 $3.49 Billion $130.95 Million 0.038x -42.36%
2018-12-31 $3.48 Billion $226.37 Million 0.065x +10.92%
2017-12-31 $3.73 Billion $218.77 Million 0.059x -26.49%
2016-12-31 $3.09 Billion $246.97 Million 0.080x -14.42%
2015-12-31 $3.26 Billion $303.81 Million 0.093x -18.92%
2014-12-31 $3.35 Billion $385.76 Million 0.115x -12.91%
2013-12-31 $2.74 Billion $362.17 Million 0.132x +73.40%
2012-12-31 $2.16 Billion $164.30 Million 0.076x -74.77%
2011-12-31 $189.28 Million $57.15 Million 0.302x +5.44%
2010-12-31 $216.37 Million $61.97 Million 0.286x +48.73%
2009-12-31 $198.83 Million $38.29 Million 0.193x +202.00%
2008-12-31 $166.93 Million $-31.51 Million -0.189x -113.45%
2007-12-31 $53.05 Million $74.48 Million 1.404x +147.72%
2006-12-31 $5.90 Million $-17.36 Million -2.942x -387.56%
2005-12-31 $-7.58 Million $-7.75 Million 1.023x --

About Enovis Corp

NYSE:ENOV USA Medical Devices
Market Cap
$1.57 Billion
Market Cap Rank
#8569 Global
#2484 in USA
Share Price
$27.16
Change (1 day)
-5.10%
52-Week Range
$17.43 - $31.51
All Time High
$91.10
About

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compres… Read more